Last updated on June 2019

Phase 3 Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)

Brief description of study

The primary objective of this study was to evaluate the efficacy of gefapixant in reducing cough frequency as measured over a 24-hour period at Week 12.

Detailed Study Description

The study had a Screening period (minimum of 7 days and up to approximately 14 days) to determine participant inclusion, a Baseline visit including 24 hours of objective measurement of cough. The study had two treatment periods (a main 12-week treatment period and a 40-week extension period), and a 14-day follow-up period.

Clinical Study Identifier: NCT03449134

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.